ind

Junshi Biosciences Announces FDAs Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients

SHANGHAI, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading…

2 months ago

India Ratings Affirms Star Health Insurance Company’s Rating at ‘IND AA+’ with a Stable Outlook

CHENNAI, India, Oct. 1, 2025 /PRNewswire/ -- Star Health and Allied Insurance Company Limited (Star Health), India's leading standalone health…

2 months ago